Quest Diagnostics Incorporated
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Quest Diagnostics Incorporated
Deal Watch: Dianthus Will Reach Public Markets Via Reverse Merger With Stalled-Out Magenta
After shutting down its trial for a leukemia conditioning agent due to a patient death, Magenta’s review of strategic alternatives concludes with a combination with complement inhibitor-focused Dianthus.
Minute Insight: Quest Diagnostics To Acquire Haystack Oncology For $300M In Cash
Quest Diagnostics will buy liquid biopsy start-up Haystack Oncology for a total of $450m with plans to launch a cancer-detection test in 2024.
Finance Watch: New Funds Keep Venture Capital Flowing Into Biopharma
Private Company Edition: In the first week of April, Cure Ventures launched with a $350m fund, the Alzheimer’s Drug Discovery Fund received $200m for its venture philanthropy strategy and Canaan revealed $850m in new funds. Also, OnKure raised $53.7m and Phlow closed a $36m series B round.
Finance Watch: Fundraising Shows Preference For Later-Stage Companies
Recent financings, including the $150m launch of Pathalys and a planned $100m IPO for Mineralys, illustrate the reality of biopharma funding in 2023 – that having near-term clinical trial milestones are key to fundraising this year. Companies with dwindling cash are conserving the funds they have left.
- In Vitro Diagnostics
- Research, Analytical Equipment & Supplies
- Other Names / Subsidiaries
- ADI Holding Company
- Athena Diagnostics
- Blueprint Genetics
- Boyce and Bynum Pathology Laboratories
- California Laboratory Associates (CLA)
- Celera Group
- Cleveland HeartLab Inc.
- Hurley Medical Center
- Pathway Diagnostics
- Shiel Medical Laboratory
- Solstas Lab Partners
- Summit Health
- Superior Mobile Medics
- Mid America Clinical Laboratories (MACL)
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.